204 related articles for article (PubMed ID: 24079661)
1. Inhibitors of cathepsin G: a patent review (2005 to present).
Kosikowska P; Lesner A
Expert Opin Ther Pat; 2013 Dec; 23(12):1611-24. PubMed ID: 24079661
[TBL] [Abstract][Full Text] [Related]
2. Identification of human cathepsin G as a functional target of boswellic acids from the anti-inflammatory remedy frankincense.
Tausch L; Henkel A; Siemoneit U; Poeckel D; Kather N; Franke L; Hofmann B; Schneider G; Angioni C; Geisslinger G; Skarke C; Holtmeier W; Beckhaus T; Karas M; Jauch J; Werz O
J Immunol; 2009 Sep; 183(5):3433-42. PubMed ID: 19648270
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of cathepsin C (dipeptidyl peptidase I).
Laine DI; Busch-Petersen J
Expert Opin Ther Pat; 2010 Apr; 20(4):497-506. PubMed ID: 20205619
[TBL] [Abstract][Full Text] [Related]
4. Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).
Tsai YF; Hwang TL
Expert Opin Ther Pat; 2015; 25(10):1145-58. PubMed ID: 26118988
[TBL] [Abstract][Full Text] [Related]
5. 5-Lipoxygenase inhibitors: a review of recent patents (2010-2012).
Hofmann B; Steinhilber D
Expert Opin Ther Pat; 2013 Jul; 23(7):895-909. PubMed ID: 23600432
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of cathepsin K: a patent review (2004 - 2010).
Wijkmans J; Gossen J
Expert Opin Ther Pat; 2011 Oct; 21(10):1611-29. PubMed ID: 21923554
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of boswellic acids: a patent review (1990-2015).
Hussain H; Al-Harrasi A; Csuk R; Shamraiz U; Green IR; Ahmed I; Khan IA; Ali Z
Expert Opin Ther Pat; 2017 Jan; 27(1):81-90. PubMed ID: 27646163
[TBL] [Abstract][Full Text] [Related]
8. Introduction of non-natural amino acid residues into the substrate-specific P1 position of trypsin inhibitor SFTI-1 yields potent chymotrypsin and cathepsin G inhibitors.
Łegowska A; Debowski D; Lesner A; Wysocka M; Rolka K
Bioorg Med Chem; 2009 May; 17(9):3302-7. PubMed ID: 19362846
[TBL] [Abstract][Full Text] [Related]
9. Homogeneous, Synthetic, Non-Saccharide Glycosaminoglycan Mimetics as Potent Inhibitors of Human Cathepsin G.
Afosah DK; Fayyad RM; Puliafico VR; Merrell S; Langmia EK; Diagne SR; Al-Horani RA; Desai UR
Biomolecules; 2023 Apr; 13(5):. PubMed ID: 37238630
[TBL] [Abstract][Full Text] [Related]
10. Cathepsin B and L inhibitors: a patent review (2010 - present).
Li YY; Fang J; Ao GZ
Expert Opin Ther Pat; 2017 Jun; 27(6):643-656. PubMed ID: 27998201
[TBL] [Abstract][Full Text] [Related]
11. Phospholipase A2 inhibitors as potential therapeutic agents for the treatment of inflammatory diseases.
Magrioti V; Kokotos G
Expert Opin Ther Pat; 2010 Jan; 20(1):1-18. PubMed ID: 20021282
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in the discovery of small-molecule ATP competitive mTOR inhibitors: a patent review.
Zask A; Verheijen JC; Richard DJ
Expert Opin Ther Pat; 2011 Jul; 21(7):1109-27. PubMed ID: 21591993
[TBL] [Abstract][Full Text] [Related]
13. Histamine H4 receptor ligands and their potential therapeutic applications: an update.
Kiss R; Keserű GM
Expert Opin Ther Pat; 2012 Mar; 22(3):205-21. PubMed ID: 22385042
[TBL] [Abstract][Full Text] [Related]
14. Invariant chain processing is independent of cathepsin variation between primary human B cells/dendritic cells and B-lymphoblastoid cells.
Reich M; Zou F; Sieńczyk M; Oleksyszyn J; Boehm BO; Burster T
Cell Immunol; 2011; 269(2):96-103. PubMed ID: 21543057
[TBL] [Abstract][Full Text] [Related]
15. Antagonists of IL-1R: a patent evaluation (WO2012122985).
Sette C
Expert Opin Ther Pat; 2013 Jul; 23(7):911-4. PubMed ID: 23713714
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Neutrophil Elastase and Cathepsin G As a New Approach to the Treatment of Psoriasis: From Fundamental Biology to Development of New Target-Specific Drugs.
Krasavin MY; Gureev MA; Garabadzhiu AV; Pashkin AY; Zhukov AS; Khairutdinov VR; Samtsov AV; Shvets VI
Dokl Biochem Biophys; 2019 Jul; 487(1):272-276. PubMed ID: 31559596
[TBL] [Abstract][Full Text] [Related]
17. 2-Indolinone a versatile scaffold for treatment of cancer: a patent review (2008-2014).
Leoni A; Locatelli A; Morigi R; Rambaldi M
Expert Opin Ther Pat; 2016; 26(2):149-73. PubMed ID: 26561198
[TBL] [Abstract][Full Text] [Related]
18. Lactoferrin Is an Allosteric Enhancer of the Proteolytic Activity of Cathepsin G.
Eipper S; Steiner R; Lesner A; Sienczyk M; Palesch D; Halatsch ME; Zaczynska E; Heim C; Hartmann MD; Zimecki M; Wirtz CR; Burster T
PLoS One; 2016; 11(3):e0151509. PubMed ID: 26986619
[TBL] [Abstract][Full Text] [Related]
19. Recent patents in the discovery of small molecule inhibitors of JAK3.
Wilson LJ
Expert Opin Ther Pat; 2010 May; 20(5):609-23. PubMed ID: 20402545
[TBL] [Abstract][Full Text] [Related]
20. Cathepsin G and its Dichotomous Role in Modulating Levels of MHC Class I Molecules.
Burster T; Knippschild U; Molnár F; Zhanapiya A
Arch Immunol Ther Exp (Warsz); 2020 Aug; 68(4):25. PubMed ID: 32815043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
